As most hypertensive patients are likely to receive several medications to treat other medical conditions associated with hypertension (e.g., kidney damage, diabetes, and heart failure), specific inhibition of sEH is an attractive target for lowering blood pressure with a minimal risk of drug–drug interactions since sEH is not primarily involved in drug metabolism. This evidence concerns the gene EPHX2 and hypertensive disorder.